elios

Highly adoptable¹

Non-thermal excimer laser²

Glaucoma intervention at the time of cataract surgery³

A sensible approach in glaucoma care.

32 million

cataract procedures are performed worldwide each year.⁴

Up to 20%

of patients undergoing cataract surgery also have glaucoma / OHT.⁵

Cataract and glaucoma are not always addressed simultaneously; present minimally-invasive glaucoma surgeries have not succeeded in making combined cataract and glaucoma treatment a 'routine.'

Drop therapy is the mainstay of glaucoma treatment but can be a burden on patients and impact their quality of life.



64% of patients on drops experience adverse side effects⁷

Lowering medication burden can have a positive effect on health-related quality of life.⁸

Glaucoma patients have

unmet needs that can be addressed

at the time of cataract surgery.

Intervention for glaucoma during the cataract surgery patients already need just makes sense.

Intervening with technology that doesn't require an implant, has been shown to provide long-term IOP reduction, and is seamlessly adopted makes even more sense.

Next generation Phaco+ technology

Scan the code to watch an animation of the ELIOS procedure.



ELIOS uses high precision, nonthermal, laser ablation to create 10 microchannels in the trabecular meshwork to enhance physiological outflow into Schlemm's canal whilst preserving angle anatomy.⁹

 \int Comparable efficacy: Phaco+ vs standalone¹⁰

The first clinically validated excimer laser MIGS¹¹

026080



IOP (>20%) for up to 8 years.⁹

Long-term microchannel patency.¹²



Up to 80% of patients are medication free one year after their surgery.¹³



Good for your patients

means good for you.



For patients with concomitant glaucoma and cataract, ELIOS is a procedure that:

Consolidates the two procedures into one²

May alleviate the burden of daily eye drops⁹

Can provide long-lasting IOP reduction⁹

Does not involve the use of an implant in the eye¹

For doctors who care for glaucoma patients, ELIOS:

- Is highly adoptable¹
- Avoids the use of an implant¹
- Offers flexibility as a combined or standalone procedure³
- Can be conveniently integrated into standard OR routines³





Highly adoptable¹

Non-thermal excimer laser²

Glaucoma intervention at the time of cataract surgery³

elios – it just makes sense.

References

- 1. Durr et al. Eye and Vision. 2020.
- 2. Pidro A, Biscevic A, Pjano MA, Mravicic I, Bejdic N, Bohac M. Acta Inform Med. 2019 Dec.
- 3. Töteberg-Harms, M., Hanson, J.V. & Funk, J. BMC Ophthalmol. 2013 Jun.
- 4. Tseng VL, Yu F, Lum F, Coleman AL. JAMA. 2012 Aug.
- 5. Hughes R, Aristodemou P, Sparrow JM, Kaye S. Br J Ophthalmol. 2021 Nov.
- 6. Omoti AE, Ukponmwan CU. Seguimiento Farmacoterapéutico. 2005.
- 7. Nordmann, JP, Auzanneau, N., Ricard, S. et al. Health Qual Life Outcomes. 2003.
- 8. Quaranta L, Riva I, Gerardi C, Oddone F, Floriani I, Konstas AG. Adv Ther. 2016 Jun.
- 9. Riesen M, Funk J, Töteberg-Harms M. Graefes Arch Clin Exp Ophthalmol. 2022 May.
- 10. Berlin MS, Shakibkhou J, Tilakaratna N, Giers U, Groth SL. J Cataract Refract Surg. 2022 Jul.
- 11. Nguyen A, Simon B, Doan R, Chen E, Lamrani R, Shakibkhou J, Berlin MS. J Clin Med. 2022 Jun.
- 12. Data on file.
- 13. Moreno Valladares A, Puerto Amorós N, Mendez Llatas M, Pazos López M, Ahmed IIK. Arch Soc Esp Oftalmol (Engl Ed). 2021 Mar.

elios vision

eliosvision.com

ELIOS Vision GmbH is the EU distributor of ELIOS manufactured by MLase AG, located at 82110 Germering, Industriestr. 17 and the FIDO laser applicator manufactured by WEINERT Fiber Optics GmbH, Mittlere-Motsch-Strasse 26, 96515 Sonneberg, Germany. ELIOS is CE marked and licensed for use in the EU in adult patients with glaucoma and is currently under investigational use in the US as part of an ongoing IDE study (FDA). Product feedback should be sent to productsurveillance@eliosvision.com.

The ExTra II (laser class 4) has the brand name ELIOS. The ExTra II is equivalent to ExTra and AIDA devices.